These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 25371323)
1. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323 [TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508 [TBL] [Abstract][Full Text] [Related]
4. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403 [TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187 [TBL] [Abstract][Full Text] [Related]
6. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of pemetrexed with sorafenib in advanced solid tumors. Poklepovic A; Gordon S; Shafer DA; Roberts JD; Bose P; Geyer CE; McGuire WP; Tombes MB; Shrader E; Strickler K; Quigley M; Wan W; Kmieciak M; Massey HD; Booth L; Moran RG; Dent P Oncotarget; 2016 Jul; 7(27):42625-42638. PubMed ID: 27213589 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536 [TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Makielski RJ; Lubner SJ; Mulkerin DL; Traynor AM; Groteluschen D; Eickhoff J; LoConte NK Cancer Chemother Pharmacol; 2015 Aug; 76(2):317-23. PubMed ID: 26068189 [TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Hubbard JM; Kim G; Borad MJ; Johnson E; Qin R; Lensing J; Puttabasavaiah S; Wright J; Erlichman C; Grothey A Invest New Drugs; 2016 Feb; 34(1):96-103. PubMed ID: 26581401 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Kumar SK; Jett J; Marks R; Richardson R; Quevedo F; Moynihan T; Croghan G; Markovic SN; Bible KC; Qin R; Tan A; Molina J; Kaufmann SH; Erlichman C; Adjei AA Invest New Drugs; 2013 Oct; 31(5):1201-6. PubMed ID: 23887852 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Martín-Liberal J; López-Pousa A; Broto JM; Cubedo R; Gallego O; Brendel E; Tirado OM; del Muro XG Invest New Drugs; 2014 Apr; 32(2):287-94. PubMed ID: 23801301 [TBL] [Abstract][Full Text] [Related]
16. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Jamison JK; Zhou M; Gelmann EP; Luk L; Bates SE; Califano A; Fojo T Oncologist; 2024 Sep; 29(9):817-e1213. PubMed ID: 38886159 [TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Aspeslagh S; Stein M; Bahleda R; Hollebecque A; Salles G; Gyan E; Fudio S; Extremera S; Alfaro V; Soto-Matos A; Soria JC Anticancer Drugs; 2017 Mar; 28(3):341-349. PubMed ID: 27977433 [TBL] [Abstract][Full Text] [Related]
18. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622 [TBL] [Abstract][Full Text] [Related]
19. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991 [TBL] [Abstract][Full Text] [Related]